{"name":"Sara V. Latorre","slug":"sara-v-latorre","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARI-0001 cells","genericName":"ARI-0001 cells","slug":"ari-0001-cells","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Adult differentiated autologous T-cells","genericName":"Adult differentiated autologous T-cells","slug":"adult-differentiated-autologous-t-cells","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARI-0001 cells","genericName":"ARI-0001 cells","slug":"ari-0001-cells","phase":"phase_2","mechanism":"ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells.","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Adult differentiated autologous T-cells","genericName":"Adult differentiated autologous T-cells","slug":"adult-differentiated-autologous-t-cells","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}